Top

Published in:

01-10-2017 | Letter to the Editor

Optimism and the continued promise of maintenance chemotherapy

Authors: John P. Micha, Bram Goldstein, Maurie Markman

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2017

Excerpt

Advanced stage ovarian cancer is associated with a high incidence of disease progression and an overall 5-year survival rate of approximately 35% [1]. Patients who obtain a clinical remission in response to debulking surgery and induction platinum-based chemotherapy are regarded as chemo-sensitive and the extent to which they exhibit a sustained platinum free interval favorably impacts their outcome [2, 3]. Therefore, one may assert that strategies which further conduce the platinum free survival will accord a significant, therapeutic benefit. …

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928–36CrossRefPubMedPubMedCentral

Colombo N (2014) Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC Suppl 12:7–12CrossRefPubMed

Markman M (2015) Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 34:11–17CrossRefPubMed

Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465CrossRefPubMed

Makris EA, MacBarb R, Harvey DJ, Poultsides GA (2017) Surrogate end points for overall survival in metastatic, locally advanced, or unresectable pancreatic cancer: a systematic review and meta-analysis of 24 randomized controlled trials. Ann Surg Oncol 24:2371–2378CrossRefPubMed

Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncoloy Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195–198CrossRefPubMedPubMedCentral

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang H, Cella D et al. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. 2017 Society of Gynecologic Oncology Annual Meeting; National Harbor: Maryland

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115:1028–1035CrossRefPubMedPubMedCentral

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV 3rd, John CR, Markman M (2009) Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 19:239–241CrossRefPubMed

10.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Lopez KL et al (2017) Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol 80:405–410CrossRefPubMed

11.

Zhang T, Pan Q, Xiao S, Li L, Xue M (2016) Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncol Lett 11:3287–3292PubMedPubMedCentral

12.

Colombo N, Lorusso D, Scollo P (2017) Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int J Gynecol Cancer 27:1134–1140CrossRefPubMedPubMedCentral

13.

Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M et al (2017) Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach. Gynecol Oncol 146:101–108CrossRefPubMed

14.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75–87CrossRefPubMed

Title: Optimism and the continued promise of maintenance chemotherapy
Authors: John P. Micha
Bram Goldstein
Maurie Markman
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3428-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2017

Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin

Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer

Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer